Company: CMND
Filing Date: 2025-12-03
Form Type: 424B5
Source: 0001213900-25-117534
Chunk: 20

Company: Clearmind Medicine Inc.
Filing Date: 2025-12-03
Form: 424B5
Chunk 20
---
 industry; |

| ● | the                                                                                                            
 ability of our future product candidates to address needs not currently addressed by the psychedelic industry; |

| ● | our                                                                                  
 ability to obtain and maintain regulatory approval of our future product candidates; |

| ● | our                                                                                                                               
 plans relating to the further development of our future product candidates, including additional disease states or indications we 
 may pursue;                                                                                                                       |

| ● | existing                                                                              
 regulations and regulatory developments in the United States and other jurisdictions; |

| ● | our                                                                                                                               
 plans and ability to obtain or protect intellectual property rights, including extensions of patent terms where available and our 
 ability to avoid infringing the intellectual property rights of others;                                                           |

| ● | the                                                                   
 ability of our management team to oversee our drug research programs; |

<div align='center'>S-9</div>

| ● | the                                                                                     
 need to hire additional personnel and our ability to attract and retain such personnel; |

| ● | our                                                                                         
 estimates regarding expenses, future revenue, capital requirements and needs for additional 
 financing;                                                                                  |

| ● | our                          
 dependence on third parties; |

| ● | our                                                                                                                                     
 ability to compete with other companies who offer products that address similar issues that our future product candidates will address; |

| ● | our                    
 financial performance; |

| ● | the                                                                                                                               
 period over which we estimate our existing cash and cash equivalents will be sufficient to fund our future operating expenses and 
 capital expenditure requirements;                                                                                                 |

| ● | our                                                                                                              
 ability to generate revenue and profit margin under our anticipated contracts which is subject to certain risks; |

| ● | difficulties                                                                                                                        
 in our partners’ ability to recruit and retain qualified physicians and other healthcare professionals, and enforce our non-compete 
 agreements with our physicians;                                                                                                     |

| ● | our                                                                                           
 ability to restructure our operations to comply with future changes in government regulation; |

| ● | our                                                             
 ability to maintain the listing of our Common Shares on Nasdaq; |

| ● | security,                                                                                                                              
 political and economic instability in the Middle East that could harm our business, including due to the security situation in Israel; 
 and                                                                                                                                    |

| ● | those                                                                                                                
 factors referred to in our 2024 Annual Report incorporated by reference herein in “Item 3. Key Information – D. Risk 
 Factors,” “Item 4. Information on the Company,” and “Item 5. Operating and Financial Review and Prospects,”          
 as well as in our 2024 Annual